SAT0323 Adverse drug reactionsrelated to disease-modifying drugs (DMARD) in psoriatic arthritis patients in daily clinical practice

D. FreitesZulema RosalesLeticia LeónJ. FontP. LoisCristina VadilloEsperanza PatoBenjamín Fernández‐GutiérrezLuis Rodríguez‐RodríguezJuan Ángel Jover2026-03-222026-03-22201810.1136/annrheumdis-2018-eular.2577https://doi.org/10.1136/annrheumdis-2018-eular.2577https://andeanlibrary.org/handle/123456789/67155enMedicineDiscontinuationPsoriatic arthritisInternal medicinePsoriasisRetrospective cohort studyHazard ratioProportional hazards modelAdverse effectRheumatoid arthritisSAT0323 Adverse drug reactionsrelated to disease-modifying drugs (DMARD) in psoriatic arthritis patients in daily clinical practicearticle